Blog

Kamal S. Saini: Enrollment is Ongoing for Phase 3 study CAMBRIA-1

Photo taken from Kamal S. Saini/LinkedIn

May 26, 2024, 08:16

Kamal S. Saini: Enrollment is Ongoing for Phase 3 study CAMBRIA-1

Kamal S. Saini, Executive Medical Director and Head of European Medical Oncology Team at Fortrea Inc., made the following post on LinkedIn

“Approximately 4300 pts will be randomized into the early breast cancer Phase 3 study CAMBRIA-1; enrollment is ongoing!

A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
Erika Hamilton; Sibylle Loibl; Naoki Niikura; Priya Rastogi; Kamal S. Saini; Ioanna Gioni; Teresa Klinowska; Ingrid A. Mayer; Mary Stuart; Emilia Syta; Andrew Walding; Thomas Bachelot.”

Kamal S. Saini

Read further.
Source: Kamal S. Saini/LinkedIn
.

4300 pts Andrew Walding CAMBRIA-1 camizestrant cancer early breast cancer Emilia Syta enrollment ongoing ER+/HER2– Erika Hamilton Executive Medical Director extended adjuvant therapy Fortrea Inc. Head of European Medical Oncology Team high risk of recurrence Ingrid A. Mayer intermediate risk Ioanna Gioni Kamal S. Saini Mary Stuart Naoki Niikura OncoDaily Oncology Phase 3 study Priya Rastogi randomized open-label study Sibylle Loibl standard endocrine therapy Teresa Klinowska Thomas Bachelot

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer